FSD Pharma has received FDA permission to design and submit an application for a new trial using a synthetic cannabinoid-based drug in the... Drug Trial Planned for Synthetic Cannabinoid COVID-19 Treatment

Philadelphia, Pennsylvania-based cannabis company FSD Pharma has been granted permission by the Food and Drug Administration to submit an Investigational New Drug Application for a clinical trial using a synthetic cannabinoid drug called ultramicronized palmitoylethanolamide (micro PEA) to treat COVID-19.

The drug is believed to act as an anti-inflammatory and is currently sold in Italy and Spain as a prescription-based nutraceutical under the brand names Normast and Pelvilen. FSD acquired the rights to micro PEA from Epitech Group, an Italian pharmaceutical firm that holds the patents for the drug until 2034, the company said.

In a press release, FSD explained that between 1969 and 1979, PEA was marketed as Impulsin by a pharmaceutical manufacturer in the former Czechoslovakia to treat influenza and the common cold. During this period, clinical trials were conducted for those uses that involved nearly 4,000 patients and volunteers across six randomized, double-blind, placebo-controlled trials. The clinical trials demonstrate that PEA has clear treatment and prophylactic effects in respiratory infections, and is safe in its use, the company said.

FSD Executive Co-Chairman and CEO Raza Bokhari called the FDA approval of concept “a paradigm shift” for the company and that it contacted the FDA in late March after finding out that some Italian physicians and scientists were advocating for the drug’s use in treating COVID-19.
Read More

MJ Shareholders avatar

MJ Shareholders

MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers

( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )